Abcam, ab265911, Human SRGN (Serglycin) knockout HeLa cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
SRGN KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 5 bp deletion in exon 1. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 5 bp deletion in exon 1,
Disease:Adenocarcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-SRGN, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Serglycin also known as hematopoietic proteoglycan core protein is a critical component of the extracellular matrix with a mass of approximately 17 kDa. It plays an important mechanical role by serving as a scaffold for the attachment of glycosaminoglycan (GAG) chains. These chains help serglycin mediate the storage and secretion of various bioactive molecules. It is expressed predominantly in hematopoietic cells including mast cells neutrophils and macrophages and also in endothelial cells serving diverse biological functions through its ability to interact with a wide variety of molecules.
Biological function summary
Serglycin acts as a mediator of cell granule storage and release processes. It is essential in the storage of secretory granules in mast cells and is involved in the process of degranulation where it participates in inflammation response and hemostasis. Serglycin associates with various proteins forming complexes with them to facilitate the storage of inflammatory mediators such as histamine and proteases. Its ability to bind to and sequester these bioactive molecules plays significant roles in the regulation of both innate and adaptive immune responses.
Pathways
Serglycin is an integral part of the inflammatory response pathway and the coagulation cascade. In the inflammatory pathway it modulates the release and activity of key cytokines and chemokines thereby participating in the regulation of immune cell recruitment and activation. In the coagulation cascade it interacts with protease inhibitors and various clotting factors to regulate coagulation processes. Serglycin's relationships with proteins like cathepsin G and elastase further illustrate its involvement in these pathways enhancing the modulation of inflammatory and hemostatic responses.
Aberrations in Serglycin function or expression have been linked to several conditions including asthma and certain types of leukemia. In asthma it may influence the severity of the disease through its role in the storage and release of inflammatory mediators in mast cells. In leukemia especially acute myeloid leukemia alterations in Serglycin expression can affect leukemic cell survival and proliferation. These links between Serglycin and disease states often involve interaction with other proteins like chymase and platelet factor 4 which contribute to disease processes.